Search research articles
Contact Us
Filters
Showing results (291-300 of 740) with videos related to
Page
of 74
Sort By:
Journal of Clinical Medicine
|
November 9, 2024
Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies
Styliani Drakoulidou, Ioannis Ntanasis-Stathopoulos, Aikaterini Kyritsi, et al.
International Journal of Cancer
|
October 11, 2008
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication
Efstathios Kastritis, Samuel Murray, Fani Kyriakou, et al.
Blood Cancer Journal
|
March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Meletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.
Leukemia & Lymphoma
|
May 14, 2016
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
Philippe Moreau, Katja C Weisel, Kevin W Song, et al.
Leukemia & Lymphoma
|
February 27, 2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
Flora Zagouri, Maria Roussou, Efstathios Kastritis, et al.
Leukemia & Lymphoma
|
September 17, 2004
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression
Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, et al.
Annals of Hematology
|
August 3, 2017
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma
Evangelos Terpos, Dimitris Matsaridis, Vassilis Koutoulidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
Proteomics
|
May 20, 2026
Peptidomic Profiling Reveals Extracellular Matrix Remodeling Signatures Discriminative of Multiple Myeloma
Maria Frantzi, Melika Ahangar, Antonia Vlahou, et al.
British Journal of Haematology
|
April 14, 2026
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial
Sosana Delimpasi, Ivan Špička, Jason P Butler, et al.
Page
of 74
Search research articles
Search
Showing results (291-300 of 740) with videos related to
Sort By:
Page
of 74
Journal of Clinical Medicine
|
November 9, 2024
Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies
Styliani Drakoulidou, Ioannis Ntanasis-Stathopoulos, Aikaterini Kyritsi, et al.
International Journal of Cancer
|
October 11, 2008
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication
Efstathios Kastritis, Samuel Murray, Fani Kyriakou, et al.
Blood Cancer Journal
|
March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Meletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.
Leukemia & Lymphoma
|
May 14, 2016
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)
Philippe Moreau, Katja C Weisel, Kevin W Song, et al.
Leukemia & Lymphoma
|
February 27, 2016
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
Flora Zagouri, Maria Roussou, Efstathios Kastritis, et al.
Leukemia & Lymphoma
|
September 17, 2004
Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression
Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, et al.
Annals of Hematology
|
August 3, 2017
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma
Evangelos Terpos, Dimitris Matsaridis, Vassilis Koutoulidis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
Proteomics
|
May 20, 2026
Peptidomic Profiling Reveals Extracellular Matrix Remodeling Signatures Discriminative of Multiple Myeloma
Maria Frantzi, Melika Ahangar, Antonia Vlahou, et al.
British Journal of Haematology
|
April 14, 2026
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial
Sosana Delimpasi, Ivan Špička, Jason P Butler, et al.
Page
of 74